Investing in Pfizer Inc (PFE): Is It a Good Value Pick?
Value investors are always on the lookout for undervalued stocks that have the potential for long-term growth. Pfizer Inc (PFE), a leading pharmaceutical company, could be a great addition to your portfolio. Here’s why: Recent price: At a recent price of $39.33, Pfizer Inc (PFE) is a stock that is suitable for Defensive Investors. Undervalued […]
Pfizer Inc Valuation – August 2016 $PFE
Pfizer Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PB ratio.
Pfizer Inc. Analysis – June 2015 Update $PFE
Pfizer performs well in the ModernGraham model and is suitable for Enterprising Investors. The Defensive Investor is concerned with the insufficient earnings growth over the last ten years, along with the poor PB ratio, while the Enterprising Investor has no initial concerns.
Pfizer Inc. Quarterly Valuation – March 2015 $PFE
Pfizer Inc. does fairly well in the ModernGraham model, and is suitable for Enterprising Investors. The Defensive Investor is concerned with the insufficient earnings growth over the last ten years, and the high PB ratio, while the Enterprising Investor has no initial concerns.
Pfizer Inc ($PFE) – Valuation May 2023
Company Profile (excerpt from Wikipedia): Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company’s largest products by sales are the Pfizer–BioNTech COVID-19 vaccine ($37 billion in 2022 revenues), Nirmatrelvir/ritonavir ($18 billion in 2022 revenues), Apixaban ($6 […]